Citing “an abundance of caution,” Novartis (NOVN: VX) has paused production of its cancer med Luthera (lutetium Lu 177 dotatate), as well as newly-approved prostate cancer therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan).
Both are radioligand therapies, which use a targeting compound to cause DNA damage that retards tumor growth and replication.
The Swiss cancer giant has stopped work on manufacturing the products at facilities in Italy and in the USA, due to “potential quality issues identified in manufacturing processes.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze